Cutting back on dietary phosphorus in addition to taking phosphate binders achieved greater decreases in serum phosphate in PD patients.
A study found that 78% of popular drinks, from flavored waters to lemonades to iced teas, contain far more phosphorus than listed in nutritional databases.
Lowest relative risk of death observed in patients with serum phosphorus and calcium levels of 4.4 mg/dL and 8.8 mg/dL, respectively.
Patients who use the supplements should have their kidney function and electrolytes monitored, researchers say.
In a study, the incidence of hyperphosphatemia, ionized hypocalcemia, and ionized hypercalcemia was 44%, 22%, and 23%, respectively.
It had a phosphorus-lowering effect similar to that of sevelamer, but had a lower pill burden.
One-third of patients who missed clinical targets for phosphorus, calcium and/or parathormone remained untreated.
Strategies to overcome motivational barriers may improve mineral bone health.
These findings underscore the need to better understand whether earlier phosphorus management influences morbidity and mortality in advanced CKD, according to researchers.
Individuals who perceived the benefits of a low-phosphorus diet and demonstrated self-efficacy were more likely to make strides against hyperphosphatemia.
Reducing dietary phosphorus is challenging, so researchers have developed a food pyramid for CKD and dialysis patients.
The findings generally support KDOQI guidelines for dialysis patients, which recommend maintaining serum phosphorus levels between 3.5 and 5.5 mg/dL.
When the kidneys are not working well, potassium levels in the blood can rise.
The medication may represent a new treatment option for dialysis patients, researchers concluded.
Investigators found that dialysis patients with serum calcium levels of 10.2 mg/dL or greater had increased risks of premature death.
Higher magnesium levels in hemodialysis patients with high phosphorus levels were associated with decreased cardiovascular mortality.
Use of these agents is associated with a much lower incidence of hypercalcemia compared with the use of calcium carbonate or calcium acetate.
Over 52 weeks, the drug maintained hemoglobin levels while decreasing IV iron use in dialysis patients with anemia.
In adjusted analyses, serum phosphorus levels independently predicted glucose disposal rate.
Each 0.5 mg/dL increment in serum phosphorus associated with 58% increased odds of coronary heart failure (CHF).
Rates for infection-, gastrointestinal-, and cardiac-related adverse events are lower than with sevelamer carbonate or calcium acetate.
Plant-based diet had the lowest urinary phosphorus excretion, whereas an inorganic-based diet had the highest.
Researchers observe significant decline in serum phosphate levels with 6 hours vs. 4 hours of treatment.
No association between phosphorus levels and all-cause mortality in women.
Every 1 mg/dL increase in serum phosphorus was independently associated with a 36% increased relative risk of kidney failure.
Study of coronary artery calcification (CAC) risk also shows serum phosphorus levels associated with nutritional intake and dialysis adequacy.
In addition to reducing serum phosphorus levels to within the recommended range, ferric citrate increases iron stores.
In a study, PA21 was as efficacious as sevelamer carbonate, but patients taking PA21 had a lower pill burden and better adherence.
Researchers observed the association among individuals with serum phosphorus levels measured after fasting for 12 or more hours.
Use is associated with fewer hospitalizations versus sevelamer carbonate and calcium acetate.
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)